Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Abbott to Market Mad Cow Tests for Cattle

By Labmedica staff writers
Posted on 29 Mar 2001
Abbott Laboratories (Abbott Park, IL, USA) has entered into an agreement with Enfer Scientific Ltd. More...
(Tipperary, Ireland) for the marketing and distribution of two diagnostic tests developed by Enfer to detect bovine encephalopathy (BSE), or mad cow disease, in cattle. Abbott will market the tests under the Enfer name.

The tests detect the presence of the abnormal prion protein associated with BSE. One test is a four-hour enzyme-linked immunosorbent assay (ELISA), approved by the European Commission. The test's rapid turnaround time and high throughput capabilities make it well suited for testing for mad cow disease. The second test is a supplemental diagnostic test used to confirm positive results of the first test. Both tests are conducted on brain tissue and spinal cord samples from cattle.

"We believe we have two very effective tests that improve the speed and reliability of BSE testing,” said Louis Ronan, director of Enfer Scientific. "By helping to ensure that only BSE-free meat enters the human food chain, these tests are making an important contribution to public safety.”




Related Links:
Abbott Diagnostics

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.